Meeting NewsVideo

VIDEO: MacroGenics CEO highlights potential of margetuximab in pretreated HER2-positive breast cancer

CHICAGO — Scott Koenig, MD, PhD, president and CEO of MacroGenics, spoke with HemOnc Today at ASCO Annual Meeting about positive results from the SOPHIA study.

The study evaluated the company’s lead molecule, margetuximab, plus chemotherapy versus trastuzumab (Herceptin, Genentech) plus chemotherapy for patients with breast cancer who had progressed on standard HER2 therapy.

The study demonstrated an improvement in PFS with the margetuximab-chemotherapy regimen. Follow-up for OS — another primary endpoint — is continuing.

Koenig also provided an overview of the company’s pipeline and highlighted data updates that should be available later this year. – by Mark Leiser

CHICAGO — Scott Koenig, MD, PhD, president and CEO of MacroGenics, spoke with HemOnc Today at ASCO Annual Meeting about positive results from the SOPHIA study.

The study evaluated the company’s lead molecule, margetuximab, plus chemotherapy versus trastuzumab (Herceptin, Genentech) plus chemotherapy for patients with breast cancer who had progressed on standard HER2 therapy.

The study demonstrated an improvement in PFS with the margetuximab-chemotherapy regimen. Follow-up for OS — another primary endpoint — is continuing.

Koenig also provided an overview of the company’s pipeline and highlighted data updates that should be available later this year. – by Mark Leiser

    See more from ASCO Annual Meeting